Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for Bexobrutideg (NX-5948) in Waldenstrom macroglobulinemia. The expected timing is based on the latest available company guidance and may change.
07/09/26:- Basket combination planning may support future WM pivotal trials.
Verification
Confirm timing and program details against the company announcement or filing.